Interleukin-17 Receptor A Antagonist [EPC]

1218 reported adverse events

Drugs of this class: BRODALUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-17 Receptor A Antagonist [EPC] class:

# Side effect Count
0 PSORIASIS 288
1 DRUG INEFFECTIVE 167
2 ARTHRALGIA 134
3 FATIGUE 106
4 PSORIATIC ARTHROPATHY 96
5 HEADACHE 86
6 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 79
7 THERAPY INTERRUPTED 78
8 INTENTIONAL PRODUCT USE ISSUE 75
9 PRODUCT DOSE OMISSION ISSUE 75
See all common reactions for Interleukin-17 Receptor A Antagonist [EPC]

Drugs of the Interleukin-17 Receptor A Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 VACCINATION SITE DISCHARGE 4 0.8000
1 ANTITHROMBIN III ABNORMAL 1 0.5000
2 LICHENOID DYSPLASIA 1 0.5000
3 ACROKERATOSIS PARANEOPLASTICA 4 0.5000
4 VACCINATION SITE VESICLES 4 0.2500
5 MATERNAL EXPOSURE VIA PARTNER DURING PREGNANCY 2 0.1429
6 VACCINATION SITE HAEMORRHAGE 4 0.1333
7 COLLAGEN-VASCULAR DISEASE 8 0.1212
8 MUCOCUTANEOUS CANDIDIASIS 7 0.1000
9 PYODERMA STREPTOCOCCAL 2 0.0952
See all enriched reactions for Interleukin-17 Receptor A Antagonist [EPC]